Objective-Low-and high-density lipoproteins (LDL and HDL) must pass the endothelial layer to exert pro-and antiatherogenic activities, respectively, within the vascular wall. However, the rate-limiting factors that mediate transendothelial transport of lipoproteins are yet little known. Therefore, we performed a high-throughput screen with kinase drug inhibitors to identify modulators of transendothelial LDL and HDL transport. Approach and Results-Microscopy-based high-content screening was performed by incubating human aortic endothelial cells with 141 kinase-inhibiting drugs and fluorescent-labeled LDL or HDL. Inhibitors of vascular endothelial growth factor (VEGF) receptors (VEGFR) significantly decreased the uptake of HDL but not LDL. Silencing of VEGF receptor 2 significantly decreased cellular binding, association, and transendothelial transport of 125 I-HDL but not 125 I-LDL. RNA interference with VEGF receptor 1 or VEGF receptor 3 had no effect. Binding, uptake, and transport of HDL but not LDL were strongly reduced in the absence of VEGF-A from the cell culture medium and were restored by the addition of VEGF-A. The restoring effect of VEGF-A on endothelial binding, uptake, and transport of HDL was abrogated by pharmacological inhibition of phosphatidyl-inositol 3 kinase/protein kinase B or p38 mitogen-activated protein kinase, as well as silencing of scavenger receptor BI. Moreover, the presence of VEGF-A was found to be a prerequisite for the localization of scavenger receptor BI in the plasma membrane of endothelial cells. Conclusions-The identification of VEGF as a regulatory factor of transendothelial transport of HDL but not LDL supports the concept that the endothelium is a specific and, hence, druggable barrier for the entry of lipoproteins into the vascular wall. Visual Overview-An online visual overview is available for this article.
A ccumulation of low-density lipoproteins (LDL) and lipids in the subendothelial matrix and macrophages is crucial in the pathogenesis of atherosclerosis. 1 Conversely, removal of cholesterol from the subendothelial space by cholesterol efflux and subsequent reverse cholesterol transport have been postulated to confer protection against atherosclerosis. 2 To reach the subendothelial space, both LDL and highdensity lipoprotein (HDL) have to cross the intact endothelial barrier. It is yet controversial whether transendothelial HDL transport is mediated by specific mechanisms or the result of passive filtration. 3, 4 Our laboratory previously showed that aortic endothelial cells are able to specifically bind, internalize, and transport HDL in a saturable and temperature-dependent manner via a nonclassical endocytic route involving dynamin and cytosketal networks. 5, 6 We also demonstrated that transcytosis of mature HDL is regulated by ATP-binding cassette transporter ABCG1, scavenger receptor BI (SR-BI), and endothelial lipase, as well as the ectopic-β ATPase/purinergic receptor axis. [6] [7] [8] Other laboratories reported that endothelial cells internalize LDL by at least 2 pathways 3 : The classical one leads to lysosomal degradation and involves clathrincoated pits and the LDL receptor. 9, 10 The other nondegrading pathway allows the transendothelial transport of LDL and involves caveolae, 11 SR-BI, 12 and activin-like kinase 1. 13 Genome-wide RNA interference studies have shown that both clathrin-and caveolin-dependent endocytosis are regulated by kinases. 14 The kinases regulating the endocytosis of lipoproteins especially by endothelial cells are unknown. To identify such signaling cascades regulating the uptake of LDL and HDL, we performed a microscopy-based high-content screening on human aortic endothelial cells (HAECs) using a kinase inhibitor drug library. Starting with this unbiased strategy, we found evidence for an important regulatory role of vascular endothelial growth factor (VEGF) and its cognate VEGF receptor-2 (VEGFR2), as well as its downstream signaling kinases in regulating uptake of HDL but not LDL by endothelial cells. The validation of this discovery did not only confirm the findings of the screen but also unraveled a regulatory role of VEGF-A on the subcellular trafficking of SR-BI.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Screening of Kinase Inhibitors
After culture for 72 hours in 384 well plates at a density of 1000 cells per well, HAECs were treated with 141 kinaseinhibiting drugs for 1 hour at 7 different dilutions spanning 4 orders of magnitude. Thereafter, cells were incubated with fluorescent-labeled Atto 594-LDL or Atto 594-HDL for another hour. After washing, fixation, and nuclei staining, 9 images per well were acquired using a molecular devices wide-field microscope. The microscope-generated images were processed by Cell profiler to segment nuclei and RFP (red fluorescent protein) foci intensity (vesicles) per cell. For each compound interaction, the amount of downregulation was calculated relative to a control reaction in the presence of vehicle (dimethyl sulfoxide). The analysis of the dose-response data for LDL and HDL uptake by the use of the Hill model (see methods) identified 2 and 9 drugs, respectively, with a Hill coefficient of 4, which, therefore, were suspicious of toxicity and, hence, excluded from further analysis (Tables I and II in the online-only Data Supplement). The drugs were preclassified as active based on their ability to fit the Hill logistic model only when the RFP foci signal dropped >50%. Finally, using Fisher exact test, we statistically evaluated the probability of finding drugs targeting a kinase that actively decrease the uptake of fluorescent LDL or HDL in the presence of maximal concentration versus nontargeting drugs. After correction of P values for multiple statistical testing, VEGFR emerged as the only target whose inhibition significantly interfered with the HDL uptake by HAECs. However, this analysis did not reveal any target whose inhibition led to a significant and consistent decrease in LDL uptake (Table) .
VEGFR2 Regulates Endothelial Binding, Association, and Transport of HDL but Not LDL
We first confirmed the regulatory role of VEGFR in the uptake of HDL by HAECs and to identify the relevant VEGF receptor by a knockdown strategy. HAECs expressed all 3 VEGF receptors: VEGFR1, VEGFR2, and VEGFR3 as analyzed by quantitative reverse transcriptase polymerase chain reaction ( Figure  IA in the online-only Data Supplement). To test which VEGF receptor was involved in HDL uptake, each of the 3 VEGF receptors was targeted using RNA interference. Although knockdown was efficient for each VEGFR on the mRNA level ( Figure IB in the online-only Data Supplement) and protein level ( Figure IC in the online-only Data Supplement), only the silencing of VEGFR2 decreased the cellular uptake of fluorescent-labeled Atto594-HDL, whereas silencing VEGFR1 and VEGFR3 showed no effect (left lane of Figure II in the online-only Data Supplement). These findings were confirmed using radioiodinated HDL, where silencing of VEGFR2 significantly reduced the specific 4°C binding of 125 I-HDL to endothelial cells by 60% ( Figure 1A ), the specific 37°C cellular association by 80% ( Figure 1B) , and the specific transendothelial transport of 125 I-HDL from apical to basal compartment at 37°C by 60% ( Figure 1C ). However, neither cellular uptake of fluorescent-labeled Atto488-LDL (right lane of Figure II 
VEGF-A Regulates Endothelial Binding, Association, and Transport of HDL but Not LDL
Binding of VEGF-A to its receptor VEGFR2 induces conformational changes and receptor dimerization, which in turn triggers kinase activation and autophosphorylation of tyrosine residues. 15 To investigate whether VEGF-A regulates transendothelial transport of HDL, we cultured endothelial cells either in the VEGF-A-containing medium A or in the VEGF-A-free medium B. The presence or absence of VEGF in the medium had no effect on the proliferation of HAECs ( Figure IIIA By contrast, cells cultured in VEGF-free medium for 72 hours did not show any decrease in the uptake of Atto488-LDL compared with the control condition (right lane of Figure  IV in the online-only Data Supplement). Likewise, presence, absence, or supplementation of VEGF-A had no effect on the cellular binding, association, and transport of 125 I-LDL ( Figure 2D , 2E, and 2F).
Taken together, these results indicate that VEGF-mediated VEGFR2 receptor activation is required for endothelial binding and uptake, as well as transendothelial transport of HDL but not LDL.
VEGF-A Regulates Endothelial Binding and Association of HDL Through p38 MitogenActivated Protein Kinase and Phosphatidylinositol 3 Kinase/Protein Kinase B
We determined whether the pharmacological inhibition of the downstream kinases of VEGF signaling, namely phosphatidyl-inositol 3 kinase (PI3K), p38 mitogen activated protein kinase (p38 MAPK), and mitogen-activated protein kinase kinase (MEK), interfere with endothelial binding and association of HDL. Cells were pretreated with indicated drugs for 30 minutes followed by pretreatment with 25 ng/ mL of VEGF-A for 1 hour at 37°C. Western blot analysis revealed that residue Ser473 of protein kinase B (Akt; the downstream kinase targeted by PI3K), residues Thr180 and Tyr182 of p38 MAPK, and residues Thr202, Tyr204, Thr185, and Tyr187 of p44/42 MAPK (ERK1/2 [extracellular signalregulated kinase], which is a common kinase target of MEK1 and MEK2) were phosphorylated in the presence but not in the absence of VEGF ( Figure IIIB in the online-only Data Supplement). Treatment with either the PI3K inhibitor wortmannin or the Akt inhibitor MK 2206 or the p38 MAPK inhibitor PD169316 decreased the cellular binding and association of 125 I-HDL. These inhibitory effects were not overcome by pretreatment with VEGF-A. Also the dual MEK1 and MEK2 inhibitor U0126 significantly decreased the cellular binding and association of 125 I-HDL. However, by contrast For each target, Fisher exact test analysis was used to calculate the probability to get more active drugs (m) and less active drugs (n) for a given target and at the same time less active drugs (m′) and more active (n′) drugs for nontargets. The drugs were preclassified as active based on their ability to fit the Hill logistic model only when the RFP (red fluorescent protein) foci signal dropped >50%. ABL indicates Abelson murine leukemia viral oncogene homolog 1; AKT, protein kinase B; ALK, anaplastic lymphoma kinase; Aurora, Aurora kinase; c-Kit, tyrosine-protein kinase kit or CD117; c-Met, tyrosine-protein kinase met; CDK, cyclin-dependent kinase; CHK, check-point kinase; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; FLT-3, fms-like tyrosine kinase 3; GSK-3, glycogen synthase kinase-3; HDL, high-density lipoprotein; HER2, receptor tyrosine-protein kinase erbB-2 or CD340; IGF-1R, insulin growth factor receptor; JAK/STAT, Janus kinase and signal transducer and activator of transcription proteins; JNK, c-Jun N-terminal kinase; LDL, low-density lipoprotein; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; p38 MAPK, p38 mitogen-activated protein kinase; PI3K/AKT, phosphotidyl-inositol 3 kinase/protein kinase B; and VEGFR, vascular endothelial growth factor receptor.
Inhibition of targets with *P≤0.01 are interpreted to be more likely than the inhibition of all other targets to decrease the uptake of LDL or HDL. The data were obtained from 2 replicate experiments.
to wortmannin, MK 2206, and PD169316, pretreatment with VEGF-A restored the inhibitory effect of U0126 on endothelial binding and association of HDL ( Figure 3A and 3B) . The effects of pharmacological inhibitors were confirmed by using RNA interference of Akt, p38 MAPK, and MEK1/MEK2. 
VEGF-A Regulates Binding, Association, and Transport of HDL via SR-BI
We have previously demonstrated that SR-BI, ABCG1, and endothelial lipase regulate binding and transendothelial transport of HDL. Because of the fast effects of VEGF-A on cellular binding, association, and transport of 125 I-HDL, we hypothesized that VEGF-A regulates the availability of one of these HDL interacting proteins on the cell surface in HAECs. To test this hypothesis, we performed a cell surface biotinylation experiment. HAECs cultured in the VEGFfree cell culture medium did not show any SR-BI on the cell surface. Pretreatment with VEGF-A restored the expression of cell surface SR-BI. By contrast, the presence or absence of VEGF-A had no effect on the cell surface expression of LDL receptor, ABCG1, or endothelial lipase (Figure 4) . To determine whether VEGF-A regulated HDL transendothelial transport through SR-BI, we silenced SR-BI using RNA interference. The knockdown was efficient at the mRNA ( Figure  VIIIA 
Discussion
We previously reported that bovine aortic endothelial cells bind, internalize, and transport HDL in a specific process dependent on SR-BI, ABCG1, 6 endothelial lipase, 7 and ectopic β-ATPase. 8 Here we show that HAECs also bind, internalize, and transport HDL, as well as LDL. Using a high-content drug screening approach, we identified VEGF-A/VEGFR2 signaling as a rate-limiting factor for the cell surface abundance of SR-BI and, as a consequence, regulator of uptake and transport of HDL by HAECs. Interestingly, VEGF-A and VEGFR2 had no effect on endothelial binding, uptake, and transport of LDL.
VEGFs are important regulators of both vasculogenesis and angiogenesis in the adult. 16 In mammals, the VEGF family encompasses 5 different isoforms namely, VEGF-A, -B, -C, and -D, as well as placenta growth factor. These ligands bind to 3 VEGF receptors-VEGFR1, VEGFR2, and VEGFR3-in an overlapping pattern. VEGF-A, VEGF-B, and placenta growth factor bind to VEGFR1 [17] [18] [19] ;
VEGF-A binds to VEGFR2 20 ; VEGF-C and VEGF-D bind to VEGFR3. 21, 22 Among VEGF-A receptors, VEGFR1 has the highest affinity and acts as a negative regulator by sequestering VEGF-A from binding to VEGFR2 23 ; hence, VEGFR2 is the key receptor mediating most of the cellular effects of VEGF-A in endothelial cells. In accordance with this, our results show that RNA interference with VEGFR2 but not with VEGFR1 decreases HDL uptake ( Figure II in the onlineonly Data Supplement). Our data show some analogy with those reported by Lim et al 24 and Martel et al, 25 who observed improved lymphatic function and transport of HDL after VEGF-C treatment in mice.
Binding of VEGF-A induces conformational changes and dimerization of VEGFR2, which in turn triggers kinase activation, tyrosine phosphorylation of the dimerized VEGFR2, and subsequent phosphorylation of SH2-containing intracellular signaling proteins, including phospholipase C-γ1, Src family tyrosine kinases, and PI3K and Ras GTPase-activating protein residues of Ras-Raf-MEK-MAPK pathway. [26] [27] [28] [29] VEGF was also shown to induce actin remodeling through activation of CDC42 and p38 MAPK. 30 Both by pharmacological inhibition and RNA interference, we revealed the involvement of PI3K/Akt, p38 MAPK, and the Ras-Raf-MEK pathway in binding and uptake of HDL (Figure 3 ; Figure VI in the online-only Data Supplement). However, the inhibition of the Ras-Raf-MEK pathway but not the inhibition of PI3K/Akt and p38 MAPK could be overcome by VEGF stimulation. Thus, VEGF regulates the interaction of HDL with endothelial cells by activating PI3K/Akt and p38 MAPK but not the Ras-Raf-MEK pathway. PI3K is known to be involved in endosomal membrane trafficking, 31, 32 and its inhibition by wortmannin in polarized cells affects early trafficking in the endocytic pathway, as well as inward vesicularization for the formation of multivesicular bodies in the later stages. 33 For example, PI3K was shown to mediate the stimulatory effect of insulin on the cell surface translocation of the glucose transporter-4. 32, 34 It has also been shown in hepatocytes that insulin regulates the cell surface expression of SR-BI and selective lipid uptake dependent on PI3K activation. 35 VEGF-A is known to stimulate actin reorganization, which in turn contributes to HDL uptake 5 and cell migration depending on activation of p38 MAPK but not ERK1/2 MAP kinase. 36, 37 Thus, it will be interesting to identify agonists beyond VEGF that regulate the endothelial binding, uptake, and transport of HDL by activating the MEK pathway. In this regard, it is also important to note our finding that RNA interference with MEK but not with Akt inhibited the binding and association of LDL with endothelial cells ( Figure VII in the online-only Data Supplement).
We found that in HAECs, VEGF-A is required for the translocation of SR-BI from intracellular compartments to the cell surface, which in turn facilitates the binding, uptake, and transport of HDL (Figures 4 and 5) . Similarly the cell-surface translocation of SR-BI is enhanced by insulin in hepatocytes 35 and by both insulin and angiotensin-II in adipocytes. 38 In hepatocytes, cell surface expression of SR-BI was shown to be dependent on PDZK1, 39 which is a tissue-specific adaptor protein with 4 PDZ domains (named after 3 proteins containing such domains: postsynaptic density protein [PSD95], Drosophila discs large [Dlg] , and the tight junction protein zonula occludens-1 [ZO-1]). However, in our hands, interference with PDZK1 did not limit the binding of HDL (data not shown) indirectly, confirming that in endothelial cells, targeting of SR-BI to the plasma membrane does not depend on PDZK1. 40 SR-BI has been shown to be involved in the protective effects of HDL on the endothelium, namely angiogenesis, migration, activation of endothelial nitric oxide synthase, and monocyte adhesion. 41 Recent studies have shown the association of enhanced expression of SR-BI expression in endothelial cells with decreased atherosclerosis in mice. 42 Thus, the requirement of VEGF on maintaining cell surface expression of SR-BI may have vascular effects beyond regulating transendothelial lipoprotein transport. HDL was previously reported to enhance hypoxiainduced angiogenesis by stimulating the expression of VEGF and VEGFR2 in endothelial cells by a mechanism involving SR-BI. 43, 44 It, thus, seems that in endothelial cells, HDL and SR-BI are both upstream regulators and downstream targets of the VEGF/VEGFR2 system. We confirmed previous reports 3,10-13 that endothelial cells internalize and transcytose LDL. We also confirmed the previous report of Armstrong et al 12 that this process involves SR-BI (Velagapudi, Rohrer, von Eckardstein, unpublished observations). However, despite regulating the cell surface abundance of SR-BI, VEGF does not regulate the transendothelial transport of LDL. Neither the interference with the VEGF receptors by drugs or RNAi nor the removal or addition of VEGF had any significant effect on the binding, uptake, or transport of LDL by HAECs. These lipoproteinspecific effects of VEGF on the processing of HDL and LDL by HAECs indicate the existence of additional regulators and routes of transendothelial transport, for example, activin-like kinase 1, which was recently identified by a genome-wide RNAi-screen as an endothelial LDL-binding protein mediating uptake and transcytosis of LDL. 13 From a more general perspective, our findings provide further evidence that transendothelial lipoprotein transport occurs by regulated processes 3,6-8,12,13 rather than passive filtration. 4 Dys-regulated transendothelial lipoprotein transport may influence the pathogenesis of atherosclerosis beyond plasma levels of LDL and HDL. In fact, it was recently shown in LDL receptor-deficient mice that acute lowering of LDL cholesterol with anti-ApoB antisense oligonucleotides rapidly reduces the permeability of the aortic endothelium for LDL and causes regression of atherosclerosis independently of LDL pool size. 45 It is less obvious how changes in arterial permeability for HDL may affect atherosclerosis. At first sight, increased availability of HDL in the subendothelium will be protective, for example, by enhancing cholesterol efflux from macrophage foam cells. However, this will only be effective if HDL also leave the arterial wall to conclude reverse cholesterol transport. Disturbed egress of HDL from the arterial wall, potentially via the lymphatics, 24, 25 will lead to the accumulation of HDL in the arterial wall. These particles will be eventually oxidized and become dysfunctional 46, 47 and, thereby, promote rather than inhibit cholesterol accumulation and, hence, atherosclerosis.
In conclusion, we here showed that the VEGF-A/VEGFR2 regulates endothelial binding, uptake, and transport of HDL through PI3K/Akt and p38 MAPK and, as the final result, cell surface expression of SR-BI. Thereby, VEGF-A may play an important regulatory role for the vascular protective effects of HDL, as well as reverse cholesterol transport.
